Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;62(8):1046-1052.
doi: 10.1111/head.14374. Epub 2022 Aug 25.

Epidemiological aspects of headache after different types of COVID-19 vaccines: An online survey

Rehab Magdy  1 , Diana Khedr  1 , Osama Yacoub  1 , Abeer Attia  2 , Mona A Abdelrahman  3 , Doaa Mekkawy  1
Affiliations

Epidemiological aspects of headache after different types of COVID-19 vaccines: An online survey

Rehab Magdy et al. Headache. 2022 Sep.

Abstract

Background: Coronavirus disease 2019 (COVID-19) vaccine-related side effects are a key concern with the emergence of various types of vaccines in the market. We aimed to assess the frequency and characteristics of headache following different types of COVID-19 vaccines.

Methods: Fully vaccinated people were recruited by a convenience sample through an online survey from September 1 to December 1, 2021. Detailed analysis of headache following vaccination was investigated. Participants with a history of pre-existing headaches were telephone interviewed by a neurologist to ascertain the type of headache.

Results: A total of 1372 participants participated (mean age 32.9 ± 11.1). The highest frequency of headache was reported with the adenoviral vector type (302/563, 53.6%), followed by mRNA vaccines (129/269, 48%) and then the inactivated type (188/540, 34.8%). Recipients of the adenoviral vector type had a significantly longer latency between vaccination and the headache onset (median 8 h [5:12]) than recipients of the inactivated type (median 4 h [2:8], p < 0.001). Headache intensity was significantly higher with the adenoviral vector type (median 6 [5:8]) than with the inactivated type (median 5 [4:7], p < 0.001). Adenoviral vector vaccines would increase the likelihood of headache by 2.38 times more than inactivated vaccines (odds ratio [OR] 2.38, 95% confidence interval [CI] 1.83-3.04, p < 0.001). Female sex and thyroid disease were significantly associated with headache related to COVID-19 vaccines (OR 1.52, 95% CI 1.16-1.99; OR 3.97, 95% CI 1.55-10.2, respectively).

Conclusion: Recipients of the COVID-19 vaccine should be counseled that they may experience headaches, especially after the adenoviral vector type. However, the intensity of such headache is mild to moderate and can resolve within a few days. Based on the current study design and the potential recall bias, these results may not be generalizable and should be preliminary.

Keywords: COVID-19 vaccines; adenoviral vector vaccine; headache; inactivated vaccine; mRNA-based vaccine.

PubMed Disclaimer

Conflict of interest statement

All authors had no disclosures.

Figures

FIGURE 1
FIGURE 1
Frequency of headache related to vaccines among the recipients of different types of COVID‐19 vaccines. p‐value ≤0.05 significant. COVID‐19, coronavirus disease 2019; mRNA, messenger RNA.
FIGURE 2
FIGURE 2
Frequency of vaccine‐related side effects among the recipients of different types of COVID‐19 vaccines. p‐value ≤0.05 significant. COVID‐19, coronavirus disease 2019; mRNA, messenger RNA.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Krammer F. SARS‐CoV‐2 vaccines in development. Nature. 2020;586:516‐527. - PubMed
    1. Kyriakidis NC, López‐Cortés A, González EV, Grimaldos AB, Prado EO. SARS‐CoV‐2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6:28. - PMC - PubMed
    1. Nagy A, Alhatlani B. An overview of current COVID‐19 vaccine platforms. Comput Struct Biotechnol J. 2021;19:2508‐2517. - PMC - PubMed
    1. Mendonça SA, Lorincz R, Boucher P, Curiel DT. Adenoviral vector vaccine platforms in the SARS‐CoV‐2 pandemic. NPJ Vaccines. 2021;6:97. - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med. 2020;383:2603‐2615. - PMC - PubMed

Substances